A brief period of therapy soon after ICH onset may reduce the risk of early seizures in patients with lobar hemorrhage.

Use of DOACs in patients with ICH and AF resulted in a remarkable reduction in ischemic stroke, but that benefit was partially offset by an increase in ICH recurrence.

MIND was a prospective, open-label trial that enrolled adults up to 80 years old with moderate-large (20-80 mL) ...